An estimated 9 million US adults aged 40 years and older show signs of age-related macular degeneration (AMD).
1 Most cases of severe vision loss associated with the disease are due to advanced AMD, either central geographic atrophy or neovascular AMD, which affects an estimated 1.7 million persons.
1 An additional 7.3 million persons have early AMD, which is usually associated with moderate or no vision loss
2,3 but does increase the risk of progression to advanced AMD.
4-6 Current treatment options are limited to a minority of persons with late-stage neovascular AMD
7-12 or intermediate AMD.
13 For the large majority of persons with early or no AMD, there is no recognized means of disease prevention other than avoiding cigarette smoking.
14-16 Thus, the identification of means to prevent or delay the development of AMD would have marked public health significance.